Arecor Therapeutics Share Discussion Threads

[supernumerary] 14/3/2024 19:58

jimbo - they're up against time and some aggressive competitors. I see Novo already has an oral pill but it's not been launched because it 'requires 20 times the amount of active ingredient'. So the goal is not to produce an oral formulation, but to make one that reduces the amount of drug needed. All against the backdrop of a huge amount of interest and development in these weight loss drugs.

[jimbo123elf] 13/3/2024 06:19

They are talking about an oral version of Wegovy/Ozempic, which could be huge if they can improve upon the bioavailability of extant formulations.

[stupidboypike] 28/2/2024 11:14

We have also been promised initial results of the AT278 trial in H1 this year. The last time we got some AT278 results it triggered the share price going from 220 to 400 in very short order, so as usual, "you pays your money and you takes your choice"

Best regards SBP

[supernumerary] 28/2/2024 10:43

Thanks - I though that was the case - one of those rare cases when I seem to remember regretting missing out. Usually I'm not a fan of allowing tax to influence investment decisions - it must have been very difficult here after the big spike when one would normally sell at least some in order to lock in the profit.

Admission was early June, so I guess in 3 months' time we'll get a more accurate view of how those investors now feel...

[stupidboypike] 28/2/2024 07:57

sn, I bought most of my Arecor shares pre-IPO when it was a private company, but yes the IPO was EIS eligible, and as usual the tax lock in for EIS is 3 years.
Best regards SBP

[supernumerary] 27/2/2024 15:18

The board monitor speaks! Let me just point out that gratuitous advice is better aimed at those who might be inclined to take it. Not me, I'm afraid.

Sorry I didn't go back to the very beginning in mid-2021, although I was around here then. In fact, it more or less doubled just a few months after listing - some very over-optimistic investors - and has been falling ever since. So that's nearly 2.5 years of steadyish decline. Your 'explanation' is, to say the least, incomplete. In any event, if true, I'm somewhat surprised that Downing have managed to go below the 5% threshold without issuing a TR-1. Which fund or funds are involved?

SBP - were shares issued under EIS? If so, when does the tax lock-in expire - 3 years from listing date?

[jones1961] 27/2/2024 13:55

Please don't waste your time here Supernumerary. Arecor IPO was at 2.20, it hit a high of above 4 pounds, and was still above IPO price 9 months ago...I believe it is just what I say it is

[supernumerary] 27/2/2024 11:46

It certainly isn't just that - it's been falling pretty steadily since listing...

[stupidboypike] 27/2/2024 11:40

Jones1961 many thanks for that information, it's very helpful. Like you I believe that this price represents an extraordinary opportunity, but I am fully invested. Best regards SBP

[mdchand] 02/2/2024 12:07

hxxps://arecor.com/wp-content/uploads/2024/02/2024-02-01-New-deals-and-first-royalties.pdf

[nchanning] 01/2/2024 07:39

Seems to be the same problem with every good growth share on AIM at the moment . Market knows there's not enough cash , so it keeps drifting lower before the placing . Then management don't want to dilute too much at very low valuation so they don't raise enough cash again , and the same cycle happens again

[jonesy100] 01/2/2024 07:13

Very encouraging update this morning. At some point, maybe there will even be a market in these shares :-)

[mdchand] 24/1/2024 09:52

hxxps://www.research-tree.com/companies/uk/pharmaceuticals/arecor-therapeutics-plc/research/trinity-delta/trinity-delta-lighthouse-arecor-therapeutics/33_5cf47a4c-62c1-4c90-abbd-faaba0388850/932e22da-19b6-4758-8d81-e341b7899c20

Trinity Delta view: Sanofi’s acquisition of INBRX-101 fits in with its portfolio growth strategy and its focus and reputation in rare diseases, and the $1.7bn+ deal value underscores INBRX-101’s attractiveness. For Arecor this is further commercial validation for its formulation expertise and ability to create clearly differentiated assets. INBRX-101 is Arecor’s second most advanced partnered asset, behind biosimilar AT220 (believed to be Fresenius Kabi’s tocilizumab) which launched in Europe in H223; both emerged from a technology formulation partnership. Such partnerships are a low-risk business model generating nearterm revenues; Arecor receives research fees from day one of any formulation development collaboration under which it reformulates and develops optimised versions of a partner’s own products or product candidates. Should these convert to licences, as with AT220 and INBRX-101, there is potential for meaningful financial upside via milestones and future commercialisation income (royalties or similar). For more detail on Arecor’s investment case see our November 2023 Outlook. Our valuation remains £179m, equivalent to 583p per share.

[jonesy100] 23/1/2024 20:03

SBP, interesting comment. I also read RNS and wondered whether this is the reference to royalties... "annual technology access fees post commercialisation"

[stupidboypike] 23/1/2024 17:54

Interestingly the rns makes no mention of royalties on inbrx101. In fact it strongly suggests there aren’t royalties. That’s disappointing as the brokers note did suggest royalties. Best regards SBP

[stupidboypike] 23/1/2024 10:40

So our royalty on Inbrx-101 is listed as "low single digit". Let's be conservative and say that is 2%. Given that we have no cost of sale, or any of the risks I think it is reasonable to attribute 3% of the value of INbix-101 to Arecor. Based on $2.2b. that is $66m, or £51.8m. Our market cap is currently £51.3m. Inbx-101 is just one of many such products we have coming to market, not to mention two best in class insulin products that we own entirely. Sometimes the market throws up amazing opportunities. I believe Arecor is at that stage. I am already very heavily invested or I would be buying aggressively.

Best regards SBP

[jimbo123elf] 23/1/2024 07:19

Sanofi to acquire INBRX-101 for up to $2.2 billion.
hxxps://www.prnewswire.com/news-releases/inhibrx-announces-sale-of-inbrx-101-to-sanofi-for-an-aggregate-value-of-up-to-2-2b-302041424.html

[gleach23] 11/12/2023 18:38

Ignoring the UT closing trade of 1 share, some more chunky trades reported after the bell of 55,000 shares @ 189p and 59,348 @ 190p

[stupidboypike] 07/12/2023 09:46

updated note from Trinity:-

hxxps://www.trinitydelta.org/research-notes/second-in-house-specialty-hospital-deal/

Best regards SBP

[stupidboypike] 05/12/2023 11:03

Nice to see Manjit in action and clearly a big hitter. Feel very relaxed about my (for me) substantial Arecor investment. Best regards SBP

[127tolmers] 05/12/2023 09:53

hxxps://www.research-tree.com/media/arecor-therapeutics-reveals-deal-with-global-medical-products-company-/id/19526/06381dec-0eea-49ff-a00a-ae15276f9fc9


Proactive interview with Manjit Rahelu CBO

[127tolmers] 04/12/2023 13:16

As foreshadowed in the TD report which calculated potential values of such a deal:

Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces a co-development and exclusive licence option agreement with a leading global medical products company for a high-value, ready-to-dilute (“RTD”) oncology product from Arecor’s in-house Specialty Hospital pipeline.


Under the terms of the agreement, Arecor and its partner will conduct further co-development and regulatory work with Arecor eligible to receive potential developmental milestones. The agreement includes an option for the partner to be granted an exclusive, worldwide license to further develop and commercialise the product, with Arecor eligible to receive milestones and royalty payments.


Arecor has developed a proprietary RTD form of a lyophilized powder product using its formulation technology platform, Arestat™. This novel, liquid, RTD formulation of an existing ‘blockbuster’ oncology therapy has the potential to offer significant advantages to the current product by replacing a lengthy, resource intensive reconstitution process, promoting safe medical practices and simplifying care with reduced patient chair time.

[18bt] 04/12/2023 11:39

At some point the share price will respond to the newsflow. The Trinity Delta research is good even if "issuer paid for" - so thanks tolmers for that spot